| Bioactivity | Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells[1]. | ||||||||||||
| Invitro | Barasertib-HQPA (3 μM, 3 hours) significantly decreases expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells[1].Barasertib-hydroxyquinazoline pyrazol anilide (HQPA)] is converted rapidly to the active Barasertib-HQPA in plasma[2].Barasertib-HQPA treatment induced defective cell survival, polyploidy, and cell death in LNCaP cell line[3].Barasertib-HQPA induces a marked anti-propliferative effect accompanied by the appearance of a polyploid population, which in most cases led to apoptosis[4]. Cell Proliferation Assay[1]. Cell Line: | ||||||||||||
| Name | Barasertib-HQPA | ||||||||||||
| CAS | 722544-51-6 | ||||||||||||
| Formula | C26H30FN7O3 | ||||||||||||
| Molar Mass | 507.56 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Barasertib-HQPA
CAS: 722544-51-6 F: C26H30FN7O3 W: 507.56
Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC50 of 0.37 nM in a cell-free assay. Baraser
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.